<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    2172402
   </pmid>
   <datecreated>
    <year>
     1990
    </year>
    <month>
     12
    </month>
    <day>
     21
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1990
    </year>
    <month>
     12
    </month>
    <day>
     21
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0022-1899
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       162
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        1990
       </year>
       <month>
        Dec
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of infectious diseases
     </title>
     <isoabbreviation>
      J. Infect. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers.
    </articletitle>
    <pagination>
     <medlinepgn>
      1277-82
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      A double-blind, placebo-controlled trial was conducted to study the effects of over-the-counter analgesic/antipyretic medications on virus shedding, immune response, and clinical status in the common cold. Sixty healthy volunteers were challenged intranasally with rhinovirus type 2 and randomized to one of four treatment arms: aspirin, acetaminophen, ibuprofen, or placebo. Fifty-six volunteers were successfully infected and shed virus on at least 4 days after challenge. Virus shedding, antibody levels, clinical symptoms and signs, and blood leukocyte levels were carefully monitored. Use of aspirin and acetaminophen was associated with suppression of serum neutralizing antibody response (P less than .05 vs. placebo) and increased nasal symptoms and signs (P less than .05 vs. placebo). A concomitant rise in circulating monocytes suggested that the suppression of antibody response may be mediated through drug effects on monocytes and/or mononuclear phagocytes. There were no significant differences in viral shedding among the four groups, but a trend toward longer duration of virus shedding was observed in the aspirin and acetaminophen groups.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Community Medicine, University of Adelaide, South Australia.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Graham
      </lastname>
      <forename>
       N M
      </forename>
      <initials>
       NM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Burrell
      </lastname>
      <forename>
       C J
      </forename>
      <initials>
       CJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Douglas
      </lastname>
      <forename>
       R M
      </forename>
      <initials>
       RM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Debelle
      </lastname>
      <forename>
       P
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Davies
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Infect Dis
    </medlineta>
    <nlmuniqueid>
     0413675
    </nlmuniqueid>
    <issnlinking>
     0022-1899
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antibodies, Viral
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      103-90-2
     </registrynumber>
     <nameofsubstance>
      Acetaminophen
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      15687-27-1
     </registrynumber>
     <nameofsubstance>
      Ibuprofen
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-78-2
     </registrynumber>
     <nameofsubstance>
      Aspirin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acetaminophen
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antibodies, Viral
     </descriptorname>
     <qualifiername majortopicyn="N">
      biosynthesis
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aspirin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Common Cold
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fever
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ibuprofen
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunity
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Leukocyte Count
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Monocytes
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Phagocytes
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Rhinovirus
     </descriptorname>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
     <qualifiername majortopicyn="N">
      isolation &amp; purification
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1990
     </year>
     <month>
      12
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1990
     </year>
     <month>
      12
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1990
     </year>
     <month>
      12
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     2172402
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

